A Phase 2 interventional study of Vortioxetine and Vortioxetine in Depressive Disorder and Anxiety Disorder, sponsored by H. Lundbeck A/S. Completed at 7 sites in 2 countries. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-03-16.
Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing vortioxetine in Depressive Disorder — 1 open to participants now, 1 under way, none of them phase 3. Vortioxetine · Depressive Disorder.
Among the 10 studies testing vortioxetine in Depressive Disorder, this one is the 9th largest by enrollment, is the only one that started in 2012, is the only one in phase 2, and was the 8th registered.
855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.
Browse Depressive Disorder studies →1 of the 10 studies testing vortioxetine in Depressive Disorder is open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–65
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 7 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 7 · Phase 4 2
First in 2008; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 88 across 689 interventional studies indexed under Depressive Disorder.
Median enrollment 511 across the 10 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
H. Lundbeck A/S has 3 studies filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing vortioxetine in Depressive Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the study is to evaluate the pharmacokinetics of vortioxetine and its metabolites in connection with multiple oral dosing in child and adolescent patients with a DSM-IV-TR diagnosis of Depressive or Anxiety Disorder
The study will be conducted in the US and in Europe and will include paediatric patients diagnosed with depressive or anxiety disorders of two age populations; children aged 7-11 years and adolescents of the age 12-17 years. It is an open study to allow pharmacokinetic (PK) sampling of all patients and four dose levels will be tested. Following lower initial doses for 2 to 6 days, the patients will be treated once daily at the assigned dose levels for 14 days, and it is expected that patients may benefit from treatment during this period. As the treatment duration is not sufficient according to treatment guidelines, if judged or indicated by the investigator, the patients are offered to continue in an extension treatment of up to six months to allow possibility for therapeutic satisfaction.
Preferably, the cohorts will be dosed in the following order: AC1, AC2, CC1, AC3, CC2, AC4, CC3, and CC4. An external data safety monitoring board (DSMB) will be established to evaluate safety, tolerability and preliminary PK data from the dosed cohort(s) prior to any dosing of subsequent cohort (s). The dose regimen may be adjusted based on the recommendation of the DSMB. Adolescents will be exposed to a certain dose of vortioxetine before children receive the same dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vortioxetine
Drug: Vortioxetine
Drug: Vortioxetine
Drug: Vortioxetine
Drug: Vortioxetine
Drug: Vortioxetine
Drug: Vortioxetine
Drug: Vortioxetine
5 mg tablets for 14 days; orally; once daily
Also known as: Brintellix
10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily
Also known as: Brintellix
15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily
Also known as: Brintellix
20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
Also known as: Brintellix
Cmax of Vortioxetine
Maximum plasma concentration of vortioxetine
Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18, or 20, depending on assigned dose level
AUC(0-24h) of Vortioxetine
Area under the vortioxetine plasma concentration-time curve from 0 to 24 hours
Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level
t½ of Vortioxetine
Half-life of vortioxetine in plasma
Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level
Cmax of Lu AA34443
Maximum plasma concentration of the major, inactive metabolite Lu AA34443
Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18, or 20, depending on assigned dose level
AUC(0-24h) of Lu AA34443
Area under the plasma concentration-time curve from 0 to 24 hours for the major, inactive metabolite Lu AA34443
Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level
t½ of Lu AA34443
Half-life of the major, inactive metabolite Lu AA34443 in plasma
Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level
Oral Clearance (CL/F) of Vortioxetine
Oral clearance expressed as a function of bioavailability
Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level
| Milestone | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 | 5 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Maximum plasma concentration of vortioxetine
| ng/mL | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg |
|---|---|---|---|---|---|---|---|---|
| Cmax of Vortioxetine | 4.3 ± 3.7 | 7.8 ± 2.8 | 15 ± 6.2 | 16 ± 8.1 | 5.0 ± 3.3 | 14 ± 8.2 | 26 ± 21 | 31 ± 20 |
Area under the vortioxetine plasma concentration-time curve from 0 to 24 hours
| ng*h/mL | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg |
|---|---|---|---|---|---|---|---|---|
| AUC(0-24h) of Vortioxetine | 82 ± 71 | 144 ± 60 | 283 ± 115 | 304 ± 143 | 89 ± 66 | 261 ± 137 | 492 ± 373 | 562 ± 374 |
Half-life of vortioxetine in plasma
| h | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg |
|---|---|---|---|---|---|---|---|---|
| t½ of Vortioxetine | 46 ± 33 | 56 ± 19 | 50 ± 16 | 40 ± 10 | 45 ± 27 | 52 ± 18 | 71 ± 52 | 62 ± 23 |
Maximum plasma concentration of the major, inactive metabolite Lu AA34443
| ng/mL | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg |
|---|---|---|---|---|---|---|---|---|
| Cmax of Lu AA34443 | 3.5 ± 2.2 | 14 ± 7.1 | 16 ± 5.3 | 38 ± 12 | 7.8 ± 3.4 | 15 ± 5.4 | 20 ± 13 | 47 ± 17 |
Area under the plasma concentration-time curve from 0 to 24 hours for the major, inactive metabolite Lu AA34443
| ng*h/mL | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg |
|---|---|---|---|---|---|---|---|---|
| AUC(0-24h) of Lu AA34443 | 56 ± 29 | 223 ± 98 | 266 ± 100 | 544 ± 192 | 115 ± 47 | 241 ± 93 | 429 ± 232 | 646 ± 251 |
Half-life of the major, inactive metabolite Lu AA34443 in plasma
| h | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg |
|---|---|---|---|---|---|---|---|---|
| t½ of Lu AA34443 | 26 ± 9.3 | 33 ± 13 | 24 ± 11 | 24 ± 5.1 | 20 ± 24 | 19 ± 9.6 | 29 ± 6.1 | 27 ± 8.8 |
Oral clearance expressed as a function of bioavailability
| L/h | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg |
|---|---|---|---|---|---|---|---|---|
| Oral Clearance (CL/F) of Vortioxetine | 60 ± 55 | 50 ± 16 | 50 ± 23 | 61 ± 20 | 50 ± 16 | 42 ± 25 | 29 ± 33 | 34 ± 17 |
Collected over 4 to 5 weeks, depending on the assigned dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adolescents, 5 mg | — | 0/6 (0%) | 4/6 (66.7%) |
| Adolescents, 10 mg | — | 0/6 (0%) | 4/6 (66.7%) |
| Adolescents, 15 mg | — | 0/6 (0%) | 5/6 (83.3%) |
| Adolescents, 20 mg | — | 0/6 (0%) | 5/6 (83.3%) |
| Children, 5 mg | — | 0/6 (0%) | 5/6 (83.3%) |
| Children, 10 mg | — | 0/6 (0%) | 5/6 (83.3%) |
| Children, 15 mg | — | 0/6 (0%) | 5/6 (83.3%) |
| Children, 20 mg | — | 0/6 (0%) | 4/6 (66.7%) |
| Event | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg |
|---|---|---|---|---|---|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/6 | 3/6 | 1/6 | 3/6 | 0/6 |
| NauseaGastrointestinal disorders | 2/6 | 1/6 | 3/6 | 2/6 | 2/6 | 0/6 | 1/6 | 0/6 |
| VomitingGastrointestinal disorders | 0/6 | 1/6 | 1/6 | 0/6 | 1/6 | 0/6 | 3/6 | 0/6 |
| HeadacheNervous system disorders | 3/6 | 1/6 | 2/6 | 1/6 | 2/6 | 0/6 | 2/6 | 1/6 |
| SedationNervous system disorders | 1/6 | 1/6 | 3/6 | 2/6 | 3/6 | 0/6 | 1/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 |
| FatigueGeneral disorders | 2/6 | 2/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/6 | 0/6 |
| IrritabilityGeneral disorders | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| Decreased appetiteMetabolism and nutrition disorders | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| AkathisiaNervous system disorders | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Age, Continuous(years) | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 15.7 ± 1.9 | 15.3 ± 1.9 | 15.2 ± 1.2 | 14.8 ± 1.9 | 10.3 ± 1.2 | 9.7 ± 1.2 | 10.5 ± 0.8 | 9.8 ± 1.8 | 12.7 ± 3.0 |
| Sex: Female, Male(Participants) | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 5 | 4 | 3 | 3 | 2 | 2 | 25 |
| Male | 3 | 3 | 1 | 2 | 3 | 3 | 4 | 4 | 23 |
| Race (NIH/OMB)(Participants) | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 1 | 2 | 1 | 4 | 3 | 2 | 16 |
| White | 4 | 4 | 4 | 4 | 4 | 2 | 3 | 4 | 29 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 3 |
| Region of Enrollment(participants) | Adolescents, 5 mg | Adolescents, 10 mg | Adolescents, 15 mg | Adolescents, 20 mg | Children, 5 mg | Children, 10 mg | Children, 15 mg | Children, 20 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 6 | 6 | 6 | 3 | 4 | 6 | 6 | 6 | 43 |
| Germany | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 5 |
The record gives a start of Apr 2012, a primary completion of Dec 2014 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine